Repository logo
 

British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic.

Published version
Peer-reviewed

Type

Article

Change log

Abstract

The COVID-19 pandemic is putting unprecedented pressures on healthcare systems globally. Early insights have been made possible by rapid sharing of data from China and Italy. In the UK, we have rapidly mobilised inflammatory bowel disease (IBD) centres in order that preparations can be made to protect our patients and the clinical services they rely on. This is a novel coronavirus; much is unknown as to how it will affect people with IBD. We also lack information about the impact of different immunosuppressive medications. To address this uncertainty, the British Society of Gastroenterology (BSG) COVID-19 IBD Working Group has used the best available data and expert opinion to generate a risk grid that groups patients into highest, moderate and lowest risk categories. This grid allows patients to be instructed to follow the UK government's advice for shielding, stringent and standard advice regarding social distancing, respectively. Further considerations are given to service provision, medical and surgical therapy, endoscopy, imaging and clinical trials.

Description

Keywords

crohn's colitis, crohn's disease, ulcerative colitis, Antiviral Agents, Betacoronavirus, COVID-19, Coronavirus Infections, Humans, Immunosuppressive Agents, Inflammatory Bowel Diseases, Pandemics, Pneumonia, Viral, Risk Assessment, SARS-CoV-2, United Kingdom, COVID-19 Drug Treatment

Journal Title

Gut

Conference Name

Journal ISSN

0017-5749
1468-3288

Volume Title

69

Publisher

BMJ
Sponsorship
Medical Research Council (MR/M00533X/1)